NEWSdial.com is a Resource of Well Researched Articles, Information, News, and Videos
Follow us on Twitter


 


Home > Health > Allergies
General Menu

Experimental Ragweed Pollen Allergy Therapy Shows Promise

Americans accustomed to the seasonal misery of runny noses, sneezing, and itchy, watery eyes caused by ragweed pollen soon may benefit from an experimental ragweed pollen allergy treatment that not only requires fewer injections than standard immunotherapy, but leads to a marked reduction in symptoms that persists for at least a year after therapy has stopped. This is according to a study last October in the The New England Journal of Medicine (NEJM).

The research was published in the October 5, 2006 issue.

“As many as 40 million Americans suffer from seasonal allergies caused by airborne pollens produced by grasses, trees and weeds,” says National Institutes of Health Director Elias A. Zerhouni, M.D. “Finding new therapies for allergy sufferers is certainly an important research goal.”

In the study detailed in NEJM, lead investigator Peter Creticos, M.D., medical director of the Johns Hopkins Asthma and Allergy Center in Baltimore, and his research team found that an investigational therapy based on the major ragweed allergen, Amb a 1, coupled to a unique short, synthetic sequence of DNA that stimulates the immune system, reduced allergy symptoms in adults for at least one year when given just once a week over a 6-week period. The therapeutic agent was provided by Dynavax Technologies Corp., based in Berkeley, CA.

“This innovative research holds great promise for helping people with allergies,” says NIAID Director Anthony S. Fauci, M.D. “A short course of immunotherapy that reduces allergic symptoms over an extended period of time will significantly improve the quality of life for many people.”

Ragweed is one of the most common pollens in the United States and is prevalent in the Northeast, Midwest and the South. In Baltimore, where the NEJM study was conducted, the ragweed pollen season lasts from mid-August to October. Physicians treat people suffering from mild and moderate ragweed allergies with antihistamines or nasal corticosteroids. However, when people with allergies do not respond to these treatments or experience severe symptoms, the next therapeutic option is a course of subcutaneous injections of the allergen, which is called allergen immunotherapy.

Although this standard immunotherapy is often effective, it has two major drawbacks. First, it can cause systemic allergic reactions, such as anaphylaxis, a hypersensitivity reaction that can lead to severe and sometimes life-threatening physical symptoms. Second, to provide long-lasting relief, standard immunotherapy may require frequent injections over a 3- to 5-year period. The large number of injections over such an extended period of time often results in many people not completing the treatment.

“For almost 100 years, we’ve been using the tedious process of giving allergy sufferers one to two shots a week for up to 4 to 5 years to ensure its success,” Dr. Creticos says. “This study is an important immunotherapy advance in that we’ve shown you can induce long-lasting relief from allergic rhinitis with just a few weeks of injections.”

The study initially involved 25 adult volunteers, ages 23 to 60, with a history of seasonal allergic rhinitis, positive skin test reactions to ragweed pollen, and an immediate reaction when nasally challenged with ragweed.

Prior to the start of the 2001 fall ragweed season, the study participants received six injections, each a week apart, of either the investigational therapy in increasingly higher doses or a placebo. They received no other injections throughout the course of the study. Fourteen volunteers received the study drug; 11 were given the placebo. The therapy was well-tolerated and caused only limited local reactions, which required neither medication nor change in treatment dose. No clinically significant, therapy-related adverse events occurred.

Throughout the 2001 and 2002 ragweed seasons, the volunteers were monitored for allergy-related symptoms, including the number of sneezes and the degree of post-nasal drip, allergy medication use and quality-of-life scores. Compared with the placebo recipients, the group that received the therapy experienced dramatically better outcomes that continued throughout the 2002 ragweed season even though therapy ended one year earlier. Clearly, the regimen of only six injections showed therapeutic promise when compared with the current therapy, the study authors note. However, because the results are based on a small number of volunteers and the long-term safety of the therapy is unknown, they say additional clinical trials with longer-term follow-up to adequately assess the therapy’s safety and effectiveness are necessary.

How the experimental therapy relieves ragweed allergy symptoms is not fully understood at this time. When exposed to ragweed pollen, people who are allergic to ragweed experience an increase in IgE (immunoglobulin) antibodies; immunotherapy blocks this increase in IgE. Researchers believe the experimental therapy tempers the release of immune regulatory proteins called cytokines, which blocks increases in the level of IgE antibodies.

“Using ragweed as a model allergen system with a predictable seasonal pattern of symptoms and pollen counts, it is possible to correlate pollen levels with symptoms and measure treatment effects on symptoms. This enables us to better understand immune response to allergens and serves as an approach to similar therapies to manage other allergic reactions for which there are currently no treatments, such as food allergies,” says Marshall Plaut, M.D., chief of the Allergic Mechanisms Section of NIAID’s Division of Allergy, Immunology and Transplantation.

Share/Save/Bookmark



> Subscribe to the Allergy, Sinusitis, and Asthma Ezine
> Return to Allergies Reference Section
> Return to Main Health Reference Category
>
Return to NEWSdial.com

 

Our Blogs

The Daily News

Other Sites We Run

Online Dating

Solar Power

STD Info Center

Funny Video Clips

Parkour Videos

Hidden Camera Pranks

Kindle Edition Books

Wii Games Magazine

Parp Inhibitors Cancer

Recommended Resources

Google (for search)

CNN (for news)

Our Videos

NEWSdial.com
produced these videos:

Japanese Balloon Bombs

Cute Cats

Cuddly Kittens

Newsletters

ASA Newsletter
The ASA newsletter
contains vital information on research and news related to Allergies, Sinusitis, and Asthma.
Subscribe
Archives
FAQ

Our Contact Info

NEWSdial.com
29030 Town Center Loop E.
Suite 202 - 188
Wilsonville, OR 97070
info@newsdial.com

Privacy Policy

View our Privacy Policy




NEWSdial.com is a reference directory and news resource with a focus on unique news articles.
NEWSdial.com is a customer-friendly news and reference site.
NEWSdial.com is not responsible for the content of external sites listed.
All NEWSdial.com articles are copyright 2004-2011 by NEWSdial.com. All Rights Reserved.
Online Dating Directory | Online Dating Newsletter | Joe Tracy
Webmaster Articles | Online Dating Industry
| Dating Games